Cancel
Nearby: Atlanta, GA 30308

Access Your Account

New to Healthgrades?

Join for free!

Or, sign in directly with Healthgrades:

Doctors and their Administrators:
Sign Up or Log In

Advances in Treating Late-Stage Lung Cancer

By

Marijke Vroomen Durning, RN

Was this helpful? (5)
This content is selected and managed by the Healthgrades editorial staff and is brought to you by an advertising sponsor.
x

This content is created or selected by the Healthgrades editorial team and is funded by an advertising sponsor. The content is subject to the Healthgrades medical review process for accuracy, balance and objectivity. The content is not edited or otherwise influenced by the advertisers appearing on this page except with the possible suggestion of the broad topic area. For more information, read the HealthGrades advertising policy.

ADVERTISEMENT

Get the FREE "Fighting Cancer With Immunotherapy" email series.  You will receive six emails with EXCLUSIVE content on immunotherapy.

*

Which of the following conditions are you MOST interested in?

By clicking "Get Started" I agree to Healthgrade's privacy policy  and user agreement.
pipette-dropping-fluid-onto-plate

Receiving a lung cancer diagnosis can be devastating. Unlike some cancers like breast cancer or skin cancer, lung cancer is often not detected until it’s advanced, which makes it harder to treat. This is often because symptoms could be easily brushed off as something less serious like an infection or for smokers, a smoker’s cough.

If you are diagnosed with lung cancer, your oncologist not only needs to know what type of lung cancer you have, but what stage the disease has reached. This can range from Stage 1, where the cancer is still confined to one lung, to Stage 4, where it has metastasized or spread to other parts of the your body, including your lymph nodes. Although later stage lung cancer is the most difficult to treat, oncologists are increasingly optimistic because there have been major advances in research over the past few years, resulting in newer and more effective treatments.

Immunotherapy

Traditionally, many type of cancers are treated with chemotherapy, which attacks the cancer cells. But chemotherapy affects other non-cancer cells as well as the cancer cells, causing potentially serious side effects. Chemotherapy is also not as effective in treating lung cancer as it is for some other types. So while chemotherapy is still used, researchers have been turning their attention to a new therapy called immunotherapy, treatment for patients with advanced lung cancers that haven’t responded to chemotherapy. It may also be used in some cases, as first-line, or initial treatment.

Immunotherapy uses specific proteins to stimulate your own immune system to find and destroy cancer cells. One of the advantages of immunotherapy is the treatment attacks only cancer cells and not the healthy cells in your body, reducing the risk of unpleasant side effects.

Currently, there are three immunotherapy medications used to treat advanced non-small cell lung cancer (NSCLC): Nivolumab (Opdivo), pembrolizumab (Keytruda) and atezolizumab (Tecentriq). Patients may get one alone, or a combination of the medications, which are given by intravenous (IV).

Like all medications, immunotherapies may have side effects. The most common one include:

  • Constipation

  • Cough

  • Diarrhea

  • Fatigue

  • Itching

  • Joint pain

  • Loss of appetite

  • Nausea

  • Skin rash

There are more serious side effects that could affect your organs, such as your lungs, intestines, liver, and kidneys, but they are rare.

Targeted Therapy

Another breakthrough treatment for advanced cancer is targeted therapy. Unlike immunotherapy which works with your immune system, targeted therapy focuses on the cancerous tumors themselves in one of three ways. Angiogenesis inhibitors prevent the tumors from growing new blood vessels. These blood vessels are essential to the tumors, providing them with the oxygen and nutrients they need to keep growing. Epidermal growth factor receptor (EGFR) inhibitors keep cancer cells from dividing and growing. A third group of medications target a tumor cell gene called ALK, which can produce a protein that causes cancer cell growth.  

Targeted therapy is not available for all cancers yet. The targeted therapy found to be most effective in treating late-stage lung cancer are generally the EGFR inhibitors, although angiogenesis inhibitors and those that target the ALK gene have been used for certain types of lung cancer. These medications can be taken by IV or by pill, depending on the particular drug. Targeted therapy can be very specific, affecting only one type of cancer cell and making one change only, or it can be broader, making several changes in the cancer cells.

Was this helpful? (5)
Medical Reviewers: William C. Lloyd III, MD, FACS Last Review Date: Dec 23, 2016

© 2016 Healthgrades Operating Company, Inc. All rights reserved. May not be reproduced or reprinted without permission from Healthgrades Operating Company, Inc. Use of this information is governed by the Healthgrades User Agreement.

View Sources

Medical References

  1. Can non-small cell lung cancer be found early? American Cancer Society. http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-detection
  2. Immunotherapy for non-small cell lung cancer. American Cancer Society. http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-treating-immunotherapy
  3. Lung Cancer. Cancer Research Institute. http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/lung-cancer
  4. Tontonoz M. Combination Immunotherapy Shows New Promise for Lung Cancer. Memorial Sloan Kettering Cancer Center. June 1, 2016. https://www.mskcc.org/blog/new-promise-combination-immunotherapy-lung-cancer
  5. Targeted therapy drugs for non-small cell lung cancer. American Cancer Society. http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-treat...

Your opinion matters!



Please fill out this short, 1-3 minute survey about Advances in Immunotherapy. Your answers are anonymous and will not be linked to you personally.

The survey will appear at the end of your visit.

Thank you!

A survey will be presented to you after you finish viewing our Advances in Immunotherapy content.

You Might Also Like

Share via Email

PREVIOUS ARTICLE:

How Immunotherapy Treats Advanced Renal Cell Carcinoma

NEXT ARTICLE:

Lung Cancer: Why See a Specialist?

Up Next

Lung Cancer: Why See a Specialist?